Latest news
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Novartis 2023 Financial Results
Novartis announces the company’s fourth quarter and 2023 full year financial results.
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
Annual Report 2023
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also contains our operating and financial results, accompanied by audited annual financial statements.
Humanitarian response
Violence against innocent people runs counter to our work to improve human health
Novartis condemns all acts of terrorism and violence. Our thoughts are with all those affected by the tragic events that continue to unfold in Israel, Gaza and the West Bank.
Novartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.